Analyst Price Target is GBX 60
▲ +207.69% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Ondine Biomedical in the last 3 months. The average price target is GBX 60, with a high forecast of GBX 60 and a low forecast of GBX 60. The average price target represents a 207.69% upside from the last price of GBX 19.50.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Ondine Biomedical.
Ondine Biomedical
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
Read More